{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:18:04Z","timestamp":1794100684896,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcpo.2026.100752","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:35:58Z","timestamp":1778859358000},"page":"100752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Regulatory approval of new oncology drugs, 2020\u20132024: A comparative analysis of FDA, EMA, and ANVISA"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2115-1436","authenticated-orcid":false,"given":"Alciellen Mendes","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Frizzera","family":"Meira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica Barreto Ribeiro","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Ruberson Ribeiro","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcpo.2026.100752_bib1","first-page":"1583","article-title":"Breast cancer treatments: drugs targeting the PI3K\/AKT\/mTOR pathway, TNBC therapy and future directions: a review","volume":"15","author":"Dynarowicz","year":"2025","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100752_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069132","article-title":"Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorization pathways, 2006\u20132021: a cross-sectional study","volume":"13","author":"Xie","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.jcpo.2026.100752_bib3","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.3390\/curroncol31080332","article-title":"New oncologic drugs from 2008 to 2023\u2014differences in approval and access between the United States, Europe and Brazil","volume":"31","author":"Barreto","year":"2024","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100752_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010\u20132019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2026.100752_bib5","first-page":"123","article-title":"Comparison of drug approvals of the FDA and EMA between 2013 and 2023","volume":"398","author":"Lau","year":"2025","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.jcpo.2026.100752_bib6","article-title":"Marketing authorization and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis","volume":"22","author":"Ivama-Brummell","year":"2023","journal-title":"Lancet Reg. Health Am."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100752_bib7","doi-asserted-by":"crossref","DOI":"10.1590\/0102-311xen148222","article-title":"Incorporation and use of medicines in the Brazilian Unified National Health System: changes and risks of new Ministry of Health legislation","volume":"39","author":"Caetano","year":"2023","journal-title":"Cad. Saude Publica"},{"key":"10.1016\/j.jcpo.2026.100752_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13023-021-01901-6","article-title":"Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases","volume":"16","author":"Miller","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jcpo.2026.100752_bib9","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100752_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1017\/S0266462319000813","article-title":"US Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer","volume":"36","author":"Ribeiro","year":"2019","journal-title":"Int J. Technol. Assess. Health Care"},{"issue":"11","key":"10.1016\/j.jcpo.2026.100752_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/GO-25-00326","article-title":"Review of all solid tumor drug approvals from 2019 to 2024 by US Food and Drug Administration, European Medicines Agency, and Brazilian Health Regulatory Agency","volume":"100567","author":"Barreto","year":"2025","journal-title":"JCO Glob. Oncol."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100752_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40273-020-00926-2","article-title":"Financing drug innovation in the US: current framework and emerging challenges","volume":"38","author":"Cutler","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100752_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1186\/s12916-024-03800-6","article-title":"Strength of clinical evidence supporting the United States Food and Drug Administration accelerated approvals from 2015 to 2022","volume":"22","author":"Zhang","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.jcpo.2026.100752_bib14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.drudis.2021.12.021","article-title":"An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020","volume":"27","author":"Wang","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.jcpo.2026.100752_bib15","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jval.2022.05.006","article-title":"Differences in evidentiary requirements between European Medicines Agency and European health technology assessment of oncology drugs\u2014can alignment be enhanced?","volume":"25","author":"Wolters","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100752_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cpt.1565","article-title":"A comparison of EMA and FDA decisions for new drug marketing applications 2014\u20132016: concordance, discordance, and why","volume":"107","author":"Kashoki","year":"2019","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jcpo.2026.100752_bib17","article-title":"Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries","volume":"45","author":"Dur\u00e1n","year":"2021","journal-title":"Rev. Panam. Salud Publica"},{"issue":"24","key":"10.1016\/j.jcpo.2026.100752_bib18","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-20-3292","article-title":"Project Orbis: global collaborative review program","volume":"26","author":"de Claro","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100752_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12962-021-00290-8","article-title":"Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact","volume":"19","author":"Millar","year":"2021","journal-title":"Cost. Eff. Resour. Alloc."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100752_bib20","first-page":"701","article-title":"Non-price-related determinants of value and access for novel non-small cell lung cancer treatments: a cross-country review of HTA decision making","volume":"5","author":"Gordon","year":"2021","journal-title":"Pharm. Open"},{"key":"10.1016\/j.jcpo.2026.100752_bib21","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1590\/1413-81232022276.16282021","article-title":"Incorpora\u00e7\u00e3o de medicamentos no SUS: compara\u00e7\u00e3o entre oncologia e componente especializado da assist\u00eancia farmac\u00eautica","volume":"27","author":"Capucho","year":"2022","journal-title":"Cien Saude Colet."},{"key":"10.1016\/j.jcpo.2026.100752_bib22","series-title":"Bras\u00edlia: Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade","article-title":"Minist\u00e9rio da Sa\u00fade. Relat\u00f3rio de recomenda\u00e7\u00e3o n\u00ba 929: pertuzumabe e trastuzumabe em combina\u00e7\u00e3o de dose fixa subcut\u00e2nea no tratamento neoadjuvante de pacientes com c\u00e2ncer de mama HER2-positivo [Internet]","author":"Brasil","year":"2024"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100752_bib23","first-page":"331","article-title":"Not cost-effective at zero price: valuing and paying for combination therapies in cancer","volume":"21","author":"Latimer","year":"2021","journal-title":"Expert Rev. Pharm. Outcomes Res"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100752_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs \u2014 a global crisis","volume":"20","author":"Lopes","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100752_bib25","article-title":"Escalating costs of innovative medicines: perspective and proposals","volume":"12","author":"Godman","year":"2024","journal-title":"Front Public Health"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:51:54Z","timestamp":1783025514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"alternative-id":["S2213538326000536"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100752","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regulatory approval of new oncology drugs, 2020\u20132024: A comparative analysis of FDA, EMA, and ANVISA","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100752"}}